HER-2 in breast cancer - Methods of detection, clinical significance and future prospects for treatment

Critical Reviews in Oncology/Hematology

Volumn 43, Issue 3, 2002, Pages 231-244

  Rampaul, R S ^a   Pinder, S E ^a   Gullick, W J ^b   Robertson, J F R ^a   Ellis, I O ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF KENT   (United Kingdom)

Author keywords

FISH; HER 2; Immunohistochemistry

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CANCER VACCINE; CHIMERIC ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GAMMA UROGASTRONE; IMMUNOTOXIN; METHOTREXATE; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; PSEUDOMONAS EXOTOXIN; RECOMBINANT ANTIBODY; TAMOXIFEN; TRASTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE THERAPY; HUMAN; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; NONHUMAN; ONCOGENE NEU; PROGNOSIS; SOUTHERN BLOTTING; TREATMENT OUTCOME; VACCINATION; VALIDATION PROCESS; ANIMAL; BREAST TUMOR; CHEMISTRY; DIAGNOSTIC PROCEDURE; FEMALE; METHODOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CANCER VACCINES; FEMALE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 0036757783     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00207-4     Document Type: Review

References (172)

1. Fearon E.F., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767.
2. Kinzler W.K., Vogelstein B., et al. Lessons from hereditary colorectal cancer. Cell. 87:1996;159-170.
3. Downward J., Yarden Y., Mayes E., et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature. 307:1984;521-527.
4. Padhy L., Shih C., Cowing D., et al. Identification of a phosphorprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell. 28:1982;865-871.
5. Schechter A.L., Stern D.F., Vaidyanathan L., et al. The neu oncogene: an erb-B-related gene encoding a 185,000 Mr tumour antigen. Nature. 312:1984;513-516.
6. Bargmann C.L., Hung M.C., Weinberg R.A. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature. 319:1986;226-230.
7. Coussens L., Yang Feng T.L., Liao Y.C., et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 230:1985;1132-1139.
8. King C.R., Kraus M.H., Aaronson S.A. Amplification of a novel v-erb-related gene in a human mammary carcinoma. Science. 229:1985;974-976.
9. Yamamoto T., Ikawa S., Akiyama T., et al. Similarity of protein encoded by the human C-erb-2 gene to epidermal growth factor receptor. Nature. 319:1986;230-234.
10. Kraus M.H., Issing M., Popescu N.C. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for over-expression in a subset of human mammary tumours. Proc. Natl. Acad. Sci. 86:1989;9193-9197.
11. Plowman G.D., Whitney G.S., Neubauer M.G., et al. Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. Proc. Natl. Acad. Sci. 87:1990;4905-4909.
12. Plowman G.D., Culouscou J.M., Whitney G.S. Ligand specific activation of HER 4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl. Acad. Sci. 90:1993;1746-1750.
13. Plowman G.D., Green J.M., Culouscou J.M., Carlton G.W. Heregulin induces tyrosine phosphorylation of HER4/p180 erbB4. Nature. 366:1993;473-475.
14. Lipponen H.J., Aaltomaa S., Syrjanen S., Syjanen K. C-erb-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer. Anticancer Res. 13:1993;1147-1152.
15. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:1987;177-182.
16. Gebhardt F., Zanker K., Brandt B. Differential expression of alternatively spliced C-erb-2 mRNA in primary tumours, lymph node metastasis, and bone marrow micro metastasis from breast cancer patients. Biochem. Biophys. Res. Commun. 247:1998;319-323.
17. Ross J.S., Fletcher J.A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells. 16:1998;413-428.
18. Revillion F., Bonneterre J., Peyrat J.P. ErbB 2 oncogene in human breast cancer and its clinical significance. Eur. J. Cancer. 34:1998;791-808.
19. Berger M.S., Locher G.W., Saurer S., et al. Correlation of Cerb-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res. 48:1988;1238-1243.
20. Van de Vijver M.J., Peterse J.L., Mooi W.J., et al. Neu-protein over-expression in breast cancer. Asoociation with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N. Engl. J. Med. 319:1988;1239-1245.
21. Heintz N.H., Leslie K.O., Rogers L.A., Howard P.L. Amplification of the C-erb-2 oncogene and prognosis of breast adenocarcinomas. Arch. Pathol. Lab. Med. 114:1990;160-163.
22. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the Her-2 proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
23. Naber S.P., Tsutsumi Y., Yin S., et al. Strategies for the analysis of oncogene over-expression. Studies of the neu oncogene in breast carcinoma. Am. J. Clin. Pathol. 94:1990;125-136.
24. Kallioniemi O.P., Kallioniemi A., Kurisu W., et al. ERBB2 amplification in breast cancer analysed by fluorescence in situ hybridization. Proc. Natl. Acad. Sci. 89:1992;5321-5325.
25. Seshadri R., Figaira F.A., Horsfall D.J., et al. Clinical significance of Her-2/neu oncogene amplification in primary breast cancer. J. Clin. Oncol. 11:1993;1936-1942.
26. Gramlitch T.L., Cohen C., Fritsch C., et al. Evaluation of Cerb-2 amplification in breast carcinoma by differential polymerase chain reaction. Am. J. Clin. Pathol. 101:1994;493-499.
27. Youngson B.J., Anelli A., Van Zee K.J., et al. Microdissection and molecular genetic analysis of Her-2 in breast carcinoma. Am. J. Surg. Pathol. 19:1995;1354-1358.
28. Smith K.L., Robbins P.D., Dawkins H.J., et al. Cerb-2 amplification in breast cancer: detection in formalin-fixed, paraffin embedded tissue by in situ hybridization. Hum. Pathol. 25:1994;413-418.
29. Pauletti G., Godolphin W., Press M.F., et al. Detection and quantitation of HER-2 gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 13:1996;63-72.
30. Persons D.L., Borelli K.A., Hsu P.H. Quantitation of HER-2 and c-myc gene amplification in breast carcinoma using fluoresence in situ hybridization. Mol. Pathol. 10:1997;720-727.
31. Dittadi R., Brazzale A., Pappagallo G., et al. ErbB 2 assay in breast cancer: Possible improved clinical information using a quantitative method. Anticancer Res. 17:1997;1245-1247.
32. Singleton T.P., Niehans G.A., Gu F., et al. Detection of Cer-b 2 activiation in paraffin-embedded tissue by immmunohistochemistry. Hum. Pathol. 23:1992;1141-1150.
33. Kerns B.J., Jordan P.A., Huper G., et al. Assessment of C erb-2 amplification by immunohistochemistry in paraffin-embedded breast cancer. Mod. Pathol. 6:1993;673-678.
34. Press M.F., Hung G., Godolphin W., et al. Sensitivity of Her-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 54:1994;2771-2777.
35. Bobrow L.G., Happerfield L.C., Millis R.R. Comparison of immunohistological staining with different antibodies to C-erb-2 oncoprotein. Appl. Immunohistochem. 4:1996;128-134.
36. Gouren D., Kim Y.S. Quantitation of erbB-2 gene copy number in breast cancer by an improved polymerase chain reaction (PCR) technique, competitively diferential PCR. Breast Cancer Res. Treat. 58:1999;213-217.
37. Jacobs T.W., Prioleau J.E., Stillman I.E., et al. Loss of tumour marker-immunostaining intensity on stored paraffin slides of breast cancer. J. Natl. Cancer Inst. 88:1996;1054-1059.
38. Penault-Llorca F., Adelaide J., Houvenaeghel G., et al. Optimization of immunohistochemical detection of Erbb 2 in human breast cancer: impact of fixation. J. Pathol. 173:1994;65-75.
39. Busmanis I., Feleppa F., Jones A., et al. Analysis of Cerb-2 expression using a panel of six commercially available antibodies. Pathology. 26:1994;261-267.
40. VanDiest P.J., vanDam P., Henzen-Logmans S.C., et al. A scoring system for immunohistochemical staining: consensus report of the Task Force for Basic Research of the EORTC-GCGC. J. Clin. Pathol. 50:1997;801-804.
41. DAKO HercepTest package insert. Carpinteria, Calif: DAKO Corp. 1998.
42. Press M.J., Bernstein L., Thomas P.A., et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node negative breast carcinomas. J. Clin. Oncol. 15:1997;2894-2904.
43. Ratcliffe N., Wells W., Wheeler K., et al. The combination of in situ hybridization and immunohistochemical analysis: an evaluation of Her-2/neu expression in paraffin embedded breast carcinomas and adjacent normal appearing breast epithelium. Mod. Pathol. 10:1997;1247-1252.
44. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of Her-2/neu in breast cancer, J Clin Oncol 1999;17:1974-1982.
45. PathVysion Her-2 package insert. Vysis, iNc, Downers Grove, III, 1998.
46. Oncor INFORM Her-2/neu Gene Dectection System. Tuscon, Ariz: Ventana Medical Systems, 1998.
47. Leitzel K., Teramoto Y., Konrad K., et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J. Clin. Oncol. 13:(5):1995;1129-1135.
48. Stearns V., Yamauchi H., Hayes D.F. Circulating tumour markers in breast cancer: accepted utilities and novel prospects. Breast Cancer Res. Treat. 52:1998;239-259.
49. Willsher P., Beaver J., Pinder S., et al. Prognostic significance of serum CerbB-2 protein in breast cancer. Breast Cancer Res. Treat. 40:1996;251-255.
50. Cheung K.L., Pinder S.E., Paish C., et al. The role of blood tumour marker measurement (using a biochemical index score and CerbB-2) in directing chemotherapy in metastatic breast cancer. Int. J. Biol. Markers. 15:(3):2000;203-209.
51. Codony-Servat J., et al. Cleavage of the Her-2 ectodomain is a pervanadate-activatable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res. 59:1999;1196-1201.
52. Harris L., Luftner D., Jager W., Robertson J.F.R. CerbB-2 in serum of patients with breast cancer. Int. J. Biol. Markers. 14:(1):1999;8-15.
53. Rilke F., Colnaghi M.I., Cascinelli N., et al. Prognostic significance of Her-2/neu expression in breast cancer and its relationship to other prognostic factors. Int. J. Cancer. 49:1991;44-49.
54. Collan Y., Haapasalo H. The value of mitotic counting in the assessment of prognosis and proliferation in human tumours. J. Pathol. 163:1991;361-362.
55. Borg Å., Tandon A.K., Sigurdsson H. Her2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 50:1990;4330-4337.
56. Gusterson B.A., Gelber R.D., Goldhirsch A., et al. Prognostic importance of c-erbB-2 expression in breast cancer. J. Clin. Oncol. 10:1992;1049-1056.
57. Wright C., Angus B., Nicholson S., et al. Expression of c erb B-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 49:1989;2087-2090.
58. Toikkanen S., Joensuu H. HER-2/neu oncoprotein as a prognostic factor in breast cancer. J. Clin. Oncol. 10:1992;1817.
59. Paik S., Hazan R., Fisher E.R., et al. Pathologic findings from the national surgical adjuvant breast and bowel project prognostic significance of erb B-2 protein over-expression in primary breast cancer. J. Clin. Oncol. 8:1989;103-112.
60. Lovekin c., Ellis I.O., Locker A., et al. CerbB2 oncoprotein expression in primary and advanced breast cancer. Br. J. Cancer. 63:1991;439-443.
61. Dati C., Muraca R., Tazartes O., et al. c-erbB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. Int. J. Cancer. 47:1991;833-888.
62. Borg Å., Baldetorp B., Fernö M., et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett. 81:1994;137-144.
63. Paik S., Hazan R., Fisher E.R., et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein over-expression in breast cancer. J. Clin. Oncol. 8:1990;103-112.
64. Battifora H., Gaffey M.J., Esteban J., et al. Immunohistochemical assay of neu/c-erbB-2 oncogene product in paraffin-embedded tissues in early breast cancer: retrospective follow-up study of 245 stage I and II cases. Modern Pathol. 4:1991;466-474.
65. Bianchi S., Paglierani M., Zampi G., et al. Prognostic significance of CerbB-2 expression in node negative breast cancer. Br. J. Cancer. 67:1993;625-629.
66. Clark G.M., McGuire W.L. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res. 51:1991;944-948.
67. Yamashita J., Ogawa M., Sakai K. Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer. Surgery. 117:1995;601-608.
68. Molina R., Ciocca D.R., Tandon A.K., et al. Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and Western blot techniques. Anticancer Res. 12:1992;1965-1971.
69. Borg Å., Baldetorp B., Fernö M., Killander D., Olsson H., Sigurdsson H. ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene. 6:1991;137-143.
70. Arguello F., Baggs R.B., Eskenazi A.E., Duerst R.E., Frantz C.N. Vascular anatomy and organ-specific tumor growth as critical factors in the development of metastases and their distribution among organs. Int. J. Cancer. 48:1991;583-590.
71. Schonborn I., Zschiesche W., Spitzer E., et al. C-erbB2-over-expression in primary breast cancer: independent prognostic factor in patients at high risk. Breast Cancer Res. Treat. 29:1994;287-295.
72. Schimmelpenning H., Eriksson E.T., Falkmer U.G., et al. Prognostic significance of immunohistochemical c-erbB-2 proto-oncogene expression and nuclear DNA content in human breast cancer. Eur. J. Surg. Oncol. 18:1992;530-537.
73. Guerin M., Barrois M., Terrier M.J., Spielmann M., Riou G. Over-expression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncog. Res. 3:1988;21-31.
74. O'Reilly S.M., Barnes D.M., Camplejohn R.S., Bartkova J., Gregory W.M., Richards M.A. The relationship between CerbB-2 expression, S-phase fraction and prognosis in breast cancer. Br. J. Cancer. 63:1991;444-446.
75. Tetu B., Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. Cancer. 73:1994;2359-2365.
76. Adnane J., Gaudray P., Simon M.P., Simony-Lafontaine J., Jeanteur P., Theillet C. Proto-oncogene amplification and breast tumor phenotype. Oncogene. 4:1989;1389-1395.
77. Tandon A.K., Clark G.M., Chamness G.C. Her2/neu oncogene protein and prognosis in breast cancer. J. Clin. Oncol. 7:1989;1120-1128.
78. Ali I.U., Campbell G., Lidereau R., Callahan R. Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma. Oncog. Res. 3:1988;139-146.
79. Kallioniemi O.-P., Holli K., Visakorpi T., Koivula T., Helin H.H., Isola J.J. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int. J. Cancer. 49:1991;650-655.
80. Kleinman H.K., Ogle R.C., Cannon F.B., Little C.D., Sweeney T.M., Luckenbill-Edds L. Laminin receptor for neurite formation. Proc. Natl. Acad. Sci. USA. 85:1988;1282-1286.
81. Allred D.C., Clark G.M., Tandon A.K., et al. HER-2/neu in node-negative breast cancer: prognostic significance of over-expression influenced by the presence of in situ carcinoma. J. Clin. Oncol. 10:1992;599-605.
82. Gullick W.J., Love S.B., Wright C., et al. c-erbB-2 Protein over-expression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br. J. Cancer. 63:1991;434-438.
83. Clark G.M. Should selection of adjuvant chemotherapy for patients with breast cancer be based on erb-2 status? J. Natl. Cancer Inst. 90:1998;1320-1321.
84. Piccart M., Awada A., Hamilton A. Integration of new therapies into management of metastatic breast cancer: a focus on chemotherapy, treatment selection through use of molecular amrkers, and newly developed biologic therapies in late clinical development. Perry M.C., Americal society of clinical oncology educational book. 1999;536-539 American Society of Clinical Oncology, Alexandria, VA.
85. Benz C.C., Scott G.K., Sarup J.C., et al. Estrogen-dependant, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with Her-2/neu. Breast Cancer Res. Treat. 24:1992;85-95.
86. Pietras R.J., Arboleda J., Reese D.M., et al. Her-2 tyrosine kinase pathway targets oestrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 10:1995;2435-2446.
87. Berns E.M.J.J., Foekens J.A., van Staveren I.L., et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene. 159:1995;11-18.
88. Bianco A.R., De Laurentis M., Carlomagno C., et al. 20 year update of the Naples GUN trial of adjuvant breast cancer therapy: evidence of interaction between C-erb-2 expression and tamoxifen efficacy. Proc. Am. Soc. Clin. Oncol. 17:1998;97A.
89. Newby J.C., Johnston S.R.D., Smith I., Dowsett M. Expression of epidermal growth factor and C-erb-2 during the development of tamoxifen resistance in human breast cancer. Clin. Cancer Res. 3:1997;16 443-16 651.
90. Nicholson R.I., Mc Celland R.A., Finlay P., et al. Relationship between EGF-R, C-erb-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur. J. Cancer. 29A:1993;1018-1023.
91. Plunkett T.A., Houston S.J., Rubens R.D., Miles D.W. C-erb-2 is a marker of resistance to endocrine therapy in advanced breast cancer. Proc. Am. Soc. Clin. Oncol. 17:1998;103a.
92. Wright C., Nicholson S., Angus B., et al. Relationship between C-erb-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br. J. Cancer. 65:1992;118-121.
93. Yamauchi H., O'Neill A., Gelman R., et al. Prediction of response to antioestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domains of the HER-2/neu protein. J. Clin. Oncol. 15:1997;2518-2525.
94. Giai M., Roagna R., Ponzone R., et al. Prognostic and predictive relevance of C-erb-2 and ras expression in node positive and negative breast cancer. Anticancer Res. 14:1994;1441-1450.
95. Archer S.G., Eliopoulos S.A., Spandidos D., et al. Expression of ras p21, p53 and C-erb-2 in advanvced breast cancer and response to first line hormonal therapy. Br. J. Cancer. 72:1995;1259-1266.
96. Elledge RM, Green, Ciocca D et al. Her-2 expression and response to tamoxifen in oestrogen receptor-positive breast cancer: a Southwest Oncology Group Study, Clin Cancer Res 1998;4:7-12.
97. Muss H., Berry D., Thor A., et al. Lack of interaction of tamoxifen (T) use and ErbB-2/HER-2/neu (H) expression in CALGB 8541: a randomized adjuvant trial of three different doses of cyclophosphamide, doxorubicin and fluorouracil (CAF) in node-positive primary breast cancer (BC). Proc. Am. Soc. Clin. Oncol. 18:1999;68a.
98. Stal O., Sullivan S., Wingren S., et al. C-erb-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur. J. Cancer. 31:1995;2185-2190.
99. Menard S., Valagussa S., Pilotti E., et al. Benefit of CMF treatment in lymph node positive breast cancer over-expressing HER-2. Proc. Am. Soc. Oncol. 18:1999;69a.
100. Miles D.W., Harris W.H., Gillett C.E., Smith P., Barnes D.M. Effect of C-erb-2 and oestrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int. J. Cancer. 84:1999;354-359.
101. Tagliabue E., Menard S., Robertson J.F.R., Harris L. c-erbB-2 Expression in primary breast cancer. Int. J. Biol. Markers. 14:(1):1999;16-26.
102. Paik S., Bryant J., Park C., et al. ErbB-2 and response to doxorubicin in patients with axillary lymph node positive, hormone receptor-negative breast cancer. J. Natl. Cancer Inst. 90:1998;1361-1370.
103. Ravin P.M., Green S., Albain V., et al. Initial report of the SWOG biological correlative study of CerbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF with tamoxifen (T) alone. Proc. Am. Soc. Clin. Oncol. 17:1998;97a.
104. Clahsen P.C., van de Velde C.J., Duval C., et al. P53 protein accumulation and response to adjuvant chemotherapy in pre-menopausal women with node-negative early breast cancer. J. Clin. Oncol. 16:1998;470-479.
105. Niskanen E., Blomqvist C., Franssila K., Hietanen P., Wasenius V.M. Predictive value of C-erb-2, p53, cathepsi-D and histology of the primary tumour in metastatic breast cancer. Br. J. Cancer. 76:1997;917-922.
106. Rozan S., Vincent-Salomon A., Zafrani B., et al. No significant predictive value of C-erb-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int. J. Cancer. 79:1998;27-33.
107. Untch M, Thomssen C, Kahlert D, et al. Lack of C-erb-2 over-expression predicts better response to dose intensification of anthracycline-based chemotherapy in high risk breast cancer. Abstract no. 110 presented at the San Antionio Breast Cancer Conference, 1998, 12-15 December.
108. Drebin J.A., Link V.C., Stern D.F., et al. Down modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell. 41:1985;697-706.
109. Drebin J.A., Link V.C., Greene M.I. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumour effects in vivo. Oncogene. 2:1988;273-277.
110. Drebin J.A., Link V.C., Greene M.I. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumour effects in vivo. Oncogene. 2:1988;387-394.
111. Fendly B.M., Winget M., Hudziac R.M., et al. Characterization of murine monoclonal antibodies reactive to either the human growth factor receptor of HER-2 gene product. Cancer Res. 50:1990;1550-1558.
112. Hancock M.C., Langton B.C., Chan T., et al. A monoclonal antibody against the C-erb-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumour cell lines. Cancer Res. 51:1991;4575-4580.
113. Harwerth I.M., Wels W., Schlegel J., et al. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br. J. Cancer. 68:1993;1140-1145.
114. McKenzie S.J., Marks P.J., Lam T., et al. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene. 4:1989;543-548.
115. Sarup J.C., Johnson R.M., King K.L., et al. Characterization of an anti-p185 monoclonal antibody that stimulates receptor functions and inhibits tumour cell growth. Growth Regul. 1:1991;72-82.
116. Scott G.K., Dodson J.M., Montgomery P.A., et al. P185 signal transduction in breast cancer cells. J. Biol. Chem. 266:1991;14 300-14 305.
117. Stancovski I., Kuwitz E., Leitner O., et al. Mechanistic aspects of the opposing effects of monoclonal antibodies to the erbB2 receptor on tumour growth. Proc. Natl. Acad. Sci. USA. 88:1991;8691-8695.
118. Hudziak R.M., Lewis G.D., Winget M., Fendly B.M., Shepard H.M., Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumour cells to tumour necrosis factor. Mol. Cell. Biol. 9:(3):1989;1165-1172.
119. Lewis G.D., Figari I., Fendly B., et al. Differential responses of the human tumour cell lines to anti-p185 monoclonal antibodies. Cancer Immunol. Immunother. 37:1993;255-263.
120. Shepard H.M., Lewis G.D., Sarup J.C., et al. Monoclonal antibody therapy of human cancer: taking the Her-2 protooncogene to the clinic. J. Clin. Immunol. 11:1991;117-127.
121. Baselga J., Norton L., Albanell J., et al. Recombinant humanized anti-HER-2 antibody (Herceptin) enhances the antitumour activity of paclitaxel and doxorubicin against HER-2/neu over-expressing human breast cancer xenographs. Cancer Res. 58:1998;2825-2831.
122. Arteaga C.L., Winnier A.R., Poirier M.C., et al. P185 C-erb-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug induced DNA repair. Cancer Res. 54:(14):1994;3758-3765.
123. Pietras R.J., Fendly B.M., Chazin V.R., et al. Antibody to Her-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. 9:1994;1829-1838.
124. Pietra R.J., Pegram M.D., Finn R.S., et al. Remission of human breast cancer xenographs on therapy with humanized monoclonal antibody to Her-2 receptor and DNA-reactive drugs. Oncogene. 17:1998;2235-2249.
125. Carter P., Presta L., Gorman C.M., et al. Humanization of an anti-p185 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA. 89:1992;4285-4289.
126. Perez E.A. Her-2 as a prognostic, predictive and therapeutic target in breast cancer. Cancer Control. 6:1999;233-240.
127. Zhao Y.Y., Sawyer D.R., Baliga R.R., et al. Neuregulins (NRG) promotes survival and growth of cardiac myocytes: persistance of Cerb-2 and Cerb-4 expression in neonatal and adult ventricular myocytes. J. Bio. Chem. 273:1998;10 261-10 269.
128. Chein K.R. Stress pathways and heart failure. Cell. 98:1999;555-558.
129. Galang C.K., Garcia-Ramirez J., Solski P.A., et al. Oncogenic Neu/ErbB increases ets, AP-1 and NF-kB dependant gene expression. J. Biol. Chem. 271:1996;7992-7998.
130. Schneider M.D., Parker T.G. Cardiac myocytes as targets for the action of peptide growth factors. Circulation. 81:1990;1443-1456.
131. Kannel W.B., Belanger A.J. Epidemiology of heart failure. Am. Heart J. 121:1991;951-957.
132. Reis LAG, Eisher MP, Kosary CL, et al. SEER Cancer Statistics Review, 1973-1997. Bethesda, MD: National Cancer Institute, 2000.
133. Disis M.L., et al. Immunity to the HER-2/neu oncogenic protein. Ciba Found Symp. 187:1994;198-207.
134. Disis M.L., Cheever M.A. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv. Cancer Res. 71:1997;343-371.
135. Fisk B., Blevins T.L., Wharton J.T., Ioannides C.G. Identification of an immunodominant peptide of HER-2/neu proto-oncogene recognized by ovarian tumour specific cytotoxic T lymphocyte lines. J. Exp. Med. 181:(6):1995;2109-2117.
136. Bernards R., Destree A., McKenzie S., Gordon E., Weinberg R.A., Panicali D. Effective tumour immunotherapy directed against an oncogene-encoded product using a vaccina virus vector. Proc. Natl. Acad. USA. 84:(19):1987;6854-9858.
137. Disis M.L., Gralow J.R., Bernhard H., Hand S.L., Rubin W.D., Cheever M.A. Peptide based but not whole protein vaccines elicit immunity to HER-2/neu, oncogenic self protein. J. Immunol. 156:(9):1996;3151-3158.
138. Nagata Y., et al. Peptides derived from a wild type murine proto-oncogene c-erbB-2/HER2 can induce CTL and tumour supression in syngenic host. J. Immunol. 159:(3):1997;1336-1343.
139. Stancovski I., Schindler D.G., Waks T., Yarden Y., Sela M., Eshhar Z. Targeting of T lymphocytes to Neu/HER2 expressing cells using chimeric chain Fv receptors. J. Immunol. 151:(11):1993;6577-6582.
140. Moritz D., Wels W., Mattern J., Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2 expressing tumour cells. Proc. Natl. Acad. Sci. USA. 91:(10):1994;4318-4322.
141. Altenschmidt U., Klundt E., Groner B. Adoptive transfer of in vitro targeted, activated T lymphocytes results in total tumour regression. J. Immunol. 159:1997;5509-5515.
142. Challita-Eid P.M., et al. A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway. J. Immunol. 160:(7):1998;3419-3426.
143. Gerstmayer B., Altenschmidt U., Hoffman M. Wels. Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the CerbB-2 protooncogene. J. Immunol. 158:1997;4584-4590.
144. Weiner L.M., et al. A human tumour xenograft model of therapy with a bispecific monoclonal antibody targeting C-erb-2 and CD 16. Cancer Res. 53:(1):1993;94-100.
145. Weiner L.M., et al. Phase 1 trial of 2B1, a bispecific monoclonal antibody targeting C-erbB2 a gamma RIII. Cancer Res. 55:(20):1995;4586-4593.
146. Curnow R.T. Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol. Immunother. 45:(3):1997;210-215.
147. Van Ojik H.H., Repp R., Groenewegen G., Valerius T., van de Winkle J.G. Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc gamma anti-HER-2/neu) in combination with granulocyte colony stimulating factor for treatment of advanced breast cancer. Cancer Immunol. Immunother. 45:(34):1997;207-209.
148. Kraus M.H., Popescu N.C., Amsbaugh S.C., King C.R. Over-expression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumour cell lines by different molecular mechanisms. EMBO J. 6:(3):1987;605-610.
149. Pasleau F, Grooteclaes M, Gol-Winkler R. Expression of the C-erbB2 gene in the BT474 human mammary tumour cell measurement of c-erbB mRNA half-life, Oncogene 8(4):849-854.
150. Ring C.J., Blouin P., Martin L.A. Use of transcriptional regulatory elements of the MUC1 and ERBB2 genes drive tumour-selective expression of a prodrug activating enzyme. Gene Therapy. 4:(10):1997;1045-1052.
151. Yu D.H., Hung M.C. Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. Oncogene. 6:(11):1991;1991-1996.
152. Chang H., Riese D.J., Gilbert W., Stern D.F., McMahan U.J. Ligands for ErbB-family receptors encoded by a neuregulin-like gene. Nature. 387:1997;509-512.
153. Ueno N.T., Yu D., Hung M.C. Chemosentization of HER-2/neu over-expressing human breast cancer cells sensitive to paclitaxel by adenovirus type 5 E1A. Oncogene. 15:(8):1997;953-960.
154. Juhl H., Downing S.G., Wellstein A., Czbayko F. HER-2/neu is rate limiting for ovarian cancer growth. Conditional depletion of HER-2/neu by ribozyme targeting. J. Biol. Chem. 272:(47):1997;29 482-29 486.
155. Deshane J., Siegal G.P., Wang M., et al. Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB2 intracellular single-chain antibody for ovarian cancer gene therapy. Gynaecol. Oncol. 64:(3):1997;378-385.
156. Hudziak R.M., Lewis G.D., Winget M., Fendly B.M., Shepard H.M., Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumour cells to tumour necrosis factor. Mol. Cell. Biol. 9:(3):1989;1165-1172.
157. Hurwitz E., Stancoski I., Sela M., Yarden Y. Suppression and promotion of tumour growth by monoclonal antibodies to erbB-2 differentially correlate with cellular uptake. Proc. Natl. Acad. Sci. USA. 92:(8):1995;3353-3357.
158. Van Leeuwen F., et al. Mutation of the human neu protein facilitates down modulation by monoclonal antibodies. Oncogene. 5:(4):1990;497-503.
159. Batra J.K., Kasprzyk P.G., Bird R.E., Pastan I., King C.R. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA. 89:(13):1992;5867-5871.
160. Groner B., et al. Intra-tumoural application of a heregulin-exotoxin fusion protein causes rat tumor regression without adverse systemic or local effects. Int. J. Cancer. 70:(6):1997;682-687.
161. Schmidt M., Hynes N.E., Groner B., Wels W. A bivalent single chain antibody-toxin specific for ErbB-2 and the EGF receptor. Int. J. Cancer. 65:(4):1996;538-546.
162. Park J.W., Hong K., Carter P., et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. USA. 92:(5):1995;1327-1331.
163. Chen S.Y., et al. Potent antitumour activity of a new class of tumour-specific killer cells. Nature. 385:(6611):1997;78-80.
164. Buchdunger E., Trinks U., Mett H., et al. 4,5-Dianilinophthalimide: a protein tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumour activity. Proc. Natl. Acad. Sci. USA. 91:1994;2334-2338.
165. Levitzki A. Typhostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB J. 6:1992;3275-3282.
166. Osherov N., Gazit A., Gilon C., Levitzki A. Selective inhibitors of the epidermal growth factor and HER-2 receptors by typhostins. J. Biol. Chem. 268:1993;1134-1142.
167. Zhang L., Chang C.J., Bacus S.S., Hung M.C. Suppressed transformation and induced differentiation of HER-2 over-expressing breast cancer cells by emodin. Cancer Res. 55:1995;3890-3896.
168. Zhang L., Lau Y.K., Xi L., et al. Tyrosine kinase inhibitors, eodin and its derivative repress HER-2 induced cellular transformation and metastasis associated properties. Oncogene. 16:1998;2855-2863.
169. Zhang L., Lau Y.K., Xia W., et al. Tyrosine kinase inhibitor emodin suppresses growth of HER-2 over-expressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin. Cancer Res. 5:1999;343-353.
170. Tsai C.M., Levitzki A., Wu L.H., et al. Enhancement of chemosensitivity by tyrphostin AG825 in high p185 (neu) expressing non-small cell lung cancer cells. Cancer Res. 56:(5):1996;1068-1074.
171. Ellis I.O., Dowsett M., Bartlett J., et al. Recommendations for HER-2 testing in the UK. J. Clin. Pathol. 53:(12):2000;890-892.
172. Thor A.D., Liu S., Edgerton S., et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J. Clin. Oncol. 18:2000;3230-3239.